LY3650150

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Perennial Allergic Rhinitis (PAR)

Phase 3

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

Active, not recruitingNCT06339008

Eli Lilly and CompanyPerennial Allergic Rhinitis (PAR)

Start: 2024-04-26End: 2028-10-01Target: 450Updated: 2026-08-24

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

RecruitingNCT06338995

Eli Lilly and CompanyChronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Start: 2024-04-29End: 2028-03-01Target: 510Updated: 2026-09-08